Prepared and filed by St Ives Burrups


Exhibit 10.8h









 May 15, 2000 

 NPS Pharmaceuticals, Inc.

  420 Chipeta Way

  Salt Lake City, Utah 84108 

 RE: Amendment Agreement 

 Dear Sirs: 

      This Amendment
  Agreement (hereinafter “Amendment Agreement”) will confirm that
  the November 1, 1993 Collaborative Research and License Agreement between NPS
  Pharmaceuticals, Inc., a corporation of the state of Delaware, having a place
  of business at 420 Chipeta Way, Salt Lake City, Utah 84108, U.S.A. (herein referred
  to as “NPS”) and SmithKline Beecham Corporation, a corporation of the Commonwealth
  of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia,
  Pennsylvania 19101, U.S.A. (hereinafter referred to as “SB”) as amended (hereinafter
  collectively referred to as “Original Agreement”) shall be further amended as
  follows:

	•	Paragraph 1.20 shall be replaced in its
      entirety with the following:
	 	 
	 	“1.20     “IND”
      shall mean an Investigational New Drug Application for COMPOUND in the FIELD
      filed by or on behalf of SB with the FDA or equivalent application(s) filed
      with the appropriate regulatory authorities in the United Kingdom, France,
      Germany, Italy, Spain or Japan, provided that the purpose of such IND is
      not to conduct experimental medicine based on a toxicology package insufficient
      to support multiple dose studies.
	 	 
	•	Paragraph 5.01 shall be amended as indicated,
      additions are indicated in bold text, deletions are indicated by
      stike through and bold text:
	 	 


	 	EFFECTIVE DATE	U.S. $ 4,000,000	 	 	 
	 	 	  	 	 	 
	 	January 1, 1995	 U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	First Program Status	U.S. $ 3,000,000	 	 	 
	 	 	  	 	 	 
	 	First Experimental Medicine IND	U.S. $ 1,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND	U.S. $ 2,000,000	 	(3,000,000)	 
	 	 	  	 	 	 
	 	NDA Filing for First COMPOUND	U.S. $ 5,000,000	 	 	 
	 	 	  	 	 	 
	 	Second Program Status	U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND for Second COMPOUND	U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	Third Program Status	U.S. $ 1,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND for Third COMPOUND	U.S. $ 1,000,000	 	 	 


Page 1






	•	Add the following as new Paragraph
      5.01(1):
	 
	     “(I)
      by the term "First Experimental Medicine IND” as used in this
      Paragraph 5.01 is meant the first Investigational New Drug Application for
      any COMPOUND in the FIELD filed by or on behalf of SB with the FDA provided
      that the purpose of such IND is to conduct experimental medicine human trials
      based on a toxicology package insufficient to support multiple dose studies.
      Multiple dose studies shall not include single doses separated by a wash-out
      period equivalent to at least 7 days or 5 half-lives of the COMPOUND.
	 
	•	This Amendment Agreement shall
      be retroactively effective as of November 1, 1993.
	 	 
	•	All other terms and conditions
      of the Original Agreement shall remain in full force and effect.


           Please
  indicate your acceptance of this Amendment
  Agreement by signing and dating the duplicate copies of this letter below and
  returning one such fully executed copy to SB. 

	 	Very truly yours,

      SMITHKLINE BEECHAM CORPORATION 
	 	 
	 	 
	 	By:	/s/ Donald F. Parman
	 	 	 Donald F. Parman
	 	Title:	Secretary
	 	Date:	May 15, 2000


 AGREED TO AND ACCEPTED:

  NPS PHARMACEUTICALS, INC. 

	By:	/s/ James K. Jensen
	  	James K. Jensen
	Title:	Vice President
	 	 
	Date:	May 15, 2000


Page 2